0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Short-acting EPO Drugs Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-5W15537
Home | Market Reports | Science| Biological Sciences
Global Short acting EPO Drugs Market Research Report 2023
BUY CHAPTERS

Global Short-acting EPO Drugs Market Research Report 2025

Code: QYRE-Auto-5W15537
Report
May 2025
Pages:94
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Short-acting EPO Drugs Market Size

The global market for Short-acting EPO Drugs was valued at US$ 10180 million in the year 2024 and is projected to reach a revised size of US$ 15420 million by 2031, growing at a CAGR of 6.2% during the forecast period.

Short-acting EPO Drugs Market

Short-acting EPO Drugs Market

Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood.
Short-acting EPO drugs have a wide range of applications in the market, primarily used for treating anemia-related conditions such as anemia associated with chronic kidney disease and in the supportive treatment of leukemia patients. The market size is substantial and continues to grow, particularly in Asian and European regions. Sales have been on the rise, reflecting increasing patient demand and benefiting from ongoing advancements in medical technology. In the future, short-acting EPO drugs are poised for further development, potentially encompassing the treatment of more anemia-related conditions and expanding their market share through innovative therapies and market expansion efforts.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Short-acting EPO Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Short-acting EPO Drugs.
The Short-acting EPO Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Short-acting EPO Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Short-acting EPO Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Short-acting EPO Drugs Market Report

Report Metric Details
Report Name Short-acting EPO Drugs Market
Accounted market size in year US$ 10180 million
Forecasted market size in 2031 US$ 15420 million
CAGR 6.2%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Epoetin-alfa
  • Epoetin-beta
  • Darbepoetin-alfa
  • Others
Segment by Application
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Amgen, Johnson & Johnson, Roche, Kyowa Kirin, LG Chem, Daewoong Pharmaceutical, Wockhardt, CJ Healthcare, 3SBio, Kexing Biopharm, Harbin Pharmaceutical Group, Beijing Four Rings Bio-Pharmaceutical
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Short-acting EPO Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Short-acting EPO Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Short-acting EPO Drugs Market growing?

Ans: The Short-acting EPO Drugs Market witnessing a CAGR of 6.2% during the forecast period 2025-2031.

What is the Short-acting EPO Drugs Market size in 2031?

Ans: The Short-acting EPO Drugs Market size in 2031 will be US$ 15420 million.

Who are the main players in the Short-acting EPO Drugs Market report?

Ans: The main players in the Short-acting EPO Drugs Market are Amgen, Johnson & Johnson, Roche, Kyowa Kirin, LG Chem, Daewoong Pharmaceutical, Wockhardt, CJ Healthcare, 3SBio, Kexing Biopharm, Harbin Pharmaceutical Group, Beijing Four Rings Bio-Pharmaceutical

What are the Application segmentation covered in the Short-acting EPO Drugs Market report?

Ans: The Applications covered in the Short-acting EPO Drugs Market report are Anemia, Kidney Disorders, Others

What are the Type segmentation covered in the Short-acting EPO Drugs Market report?

Ans: The Types covered in the Short-acting EPO Drugs Market report are Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, Others

Recommended Reports

Anemia Drugs & Therapy

Kidney Disease Markets

EPO & Related Markets

1 Short-acting EPO Drugs Market Overview
1.1 Product Definition
1.2 Short-acting EPO Drugs by Type
1.2.1 Global Short-acting EPO Drugs Market Value Comparison by Type (2024 VS 2031)
1.2.2 Epoetin-alfa
1.2.3 Epoetin-beta
1.2.4 Darbepoetin-alfa
1.2.5 Others
1.3 Short-acting EPO Drugs by Application
1.3.1 Global Short-acting EPO Drugs Market Value by Application (2024 VS 2031)
1.3.2 Anemia
1.3.3 Kidney Disorders
1.3.4 Others
1.4 Global Short-acting EPO Drugs Market Size Estimates and Forecasts
1.4.1 Global Short-acting EPO Drugs Revenue 2020-2031
1.4.2 Global Short-acting EPO Drugs Sales 2020-2031
1.4.3 Global Short-acting EPO Drugs Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Short-acting EPO Drugs Market Competition by Manufacturers
2.1 Global Short-acting EPO Drugs Sales Market Share by Manufacturers (2020-2025)
2.2 Global Short-acting EPO Drugs Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Short-acting EPO Drugs Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Short-acting EPO Drugs, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Short-acting EPO Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Short-acting EPO Drugs, Product Type & Application
2.7 Global Key Manufacturers of Short-acting EPO Drugs, Date of Enter into This Industry
2.8 Global Short-acting EPO Drugs Market Competitive Situation and Trends
2.8.1 Global Short-acting EPO Drugs Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Short-acting EPO Drugs Players Market Share by Revenue
2.8.3 Global Short-acting EPO Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Short-acting EPO Drugs Market Scenario by Region
3.1 Global Short-acting EPO Drugs Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Short-acting EPO Drugs Sales by Region: 2020-2031
3.2.1 Global Short-acting EPO Drugs Sales by Region: 2020-2025
3.2.2 Global Short-acting EPO Drugs Sales by Region: 2026-2031
3.3 Global Short-acting EPO Drugs Revenue by Region: 2020-2031
3.3.1 Global Short-acting EPO Drugs Revenue by Region: 2020-2025
3.3.2 Global Short-acting EPO Drugs Revenue by Region: 2026-2031
3.4 North America Short-acting EPO Drugs Market Facts & Figures by Country
3.4.1 North America Short-acting EPO Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Short-acting EPO Drugs Sales by Country (2020-2031)
3.4.3 North America Short-acting EPO Drugs Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Short-acting EPO Drugs Market Facts & Figures by Country
3.5.1 Europe Short-acting EPO Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Short-acting EPO Drugs Sales by Country (2020-2031)
3.5.3 Europe Short-acting EPO Drugs Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Short-acting EPO Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Short-acting EPO Drugs Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Short-acting EPO Drugs Sales by Region (2020-2031)
3.6.3 Asia Pacific Short-acting EPO Drugs Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Short-acting EPO Drugs Market Facts & Figures by Country
3.7.1 Latin America Short-acting EPO Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Short-acting EPO Drugs Sales by Country (2020-2031)
3.7.3 Latin America Short-acting EPO Drugs Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Short-acting EPO Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Short-acting EPO Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Short-acting EPO Drugs Sales by Country (2020-2031)
3.8.3 Middle East and Africa Short-acting EPO Drugs Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Short-acting EPO Drugs Sales by Type (2020-2031)
4.1.1 Global Short-acting EPO Drugs Sales by Type (2020-2025)
4.1.2 Global Short-acting EPO Drugs Sales by Type (2026-2031)
4.1.3 Global Short-acting EPO Drugs Sales Market Share by Type (2020-2031)
4.2 Global Short-acting EPO Drugs Revenue by Type (2020-2031)
4.2.1 Global Short-acting EPO Drugs Revenue by Type (2020-2025)
4.2.2 Global Short-acting EPO Drugs Revenue by Type (2026-2031)
4.2.3 Global Short-acting EPO Drugs Revenue Market Share by Type (2020-2031)
4.3 Global Short-acting EPO Drugs Price by Type (2020-2031)
5 Segment by Application
5.1 Global Short-acting EPO Drugs Sales by Application (2020-2031)
5.1.1 Global Short-acting EPO Drugs Sales by Application (2020-2025)
5.1.2 Global Short-acting EPO Drugs Sales by Application (2026-2031)
5.1.3 Global Short-acting EPO Drugs Sales Market Share by Application (2020-2031)
5.2 Global Short-acting EPO Drugs Revenue by Application (2020-2031)
5.2.1 Global Short-acting EPO Drugs Revenue by Application (2020-2025)
5.2.2 Global Short-acting EPO Drugs Revenue by Application (2026-2031)
5.2.3 Global Short-acting EPO Drugs Revenue Market Share by Application (2020-2031)
5.3 Global Short-acting EPO Drugs Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Amgen
6.1.1 Amgen Company Information
6.1.2 Amgen Description and Business Overview
6.1.3 Amgen Short-acting EPO Drugs Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Amgen Short-acting EPO Drugs Product Portfolio
6.1.5 Amgen Recent Developments/Updates
6.2 Johnson & Johnson
6.2.1 Johnson & Johnson Company Information
6.2.2 Johnson & Johnson Description and Business Overview
6.2.3 Johnson & Johnson Short-acting EPO Drugs Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Johnson & Johnson Short-acting EPO Drugs Product Portfolio
6.2.5 Johnson & Johnson Recent Developments/Updates
6.3 Roche
6.3.1 Roche Company Information
6.3.2 Roche Description and Business Overview
6.3.3 Roche Short-acting EPO Drugs Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Roche Short-acting EPO Drugs Product Portfolio
6.3.5 Roche Recent Developments/Updates
6.4 Kyowa Kirin
6.4.1 Kyowa Kirin Company Information
6.4.2 Kyowa Kirin Description and Business Overview
6.4.3 Kyowa Kirin Short-acting EPO Drugs Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Kyowa Kirin Short-acting EPO Drugs Product Portfolio
6.4.5 Kyowa Kirin Recent Developments/Updates
6.5 LG Chem
6.5.1 LG Chem Company Information
6.5.2 LG Chem Description and Business Overview
6.5.3 LG Chem Short-acting EPO Drugs Sales, Revenue and Gross Margin (2020-2025)
6.5.4 LG Chem Short-acting EPO Drugs Product Portfolio
6.5.5 LG Chem Recent Developments/Updates
6.6 Daewoong Pharmaceutical
6.6.1 Daewoong Pharmaceutical Company Information
6.6.2 Daewoong Pharmaceutical Description and Business Overview
6.6.3 Daewoong Pharmaceutical Short-acting EPO Drugs Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Daewoong Pharmaceutical Short-acting EPO Drugs Product Portfolio
6.6.5 Daewoong Pharmaceutical Recent Developments/Updates
6.7 Wockhardt
6.7.1 Wockhardt Company Information
6.7.2 Wockhardt Description and Business Overview
6.7.3 Wockhardt Short-acting EPO Drugs Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Wockhardt Short-acting EPO Drugs Product Portfolio
6.7.5 Wockhardt Recent Developments/Updates
6.8 CJ Healthcare
6.8.1 CJ Healthcare Company Information
6.8.2 CJ Healthcare Description and Business Overview
6.8.3 CJ Healthcare Short-acting EPO Drugs Sales, Revenue and Gross Margin (2020-2025)
6.8.4 CJ Healthcare Short-acting EPO Drugs Product Portfolio
6.8.5 CJ Healthcare Recent Developments/Updates
6.9 3SBio
6.9.1 3SBio Company Information
6.9.2 3SBio Description and Business Overview
6.9.3 3SBio Short-acting EPO Drugs Sales, Revenue and Gross Margin (2020-2025)
6.9.4 3SBio Short-acting EPO Drugs Product Portfolio
6.9.5 3SBio Recent Developments/Updates
6.10 Kexing Biopharm
6.10.1 Kexing Biopharm Company Information
6.10.2 Kexing Biopharm Description and Business Overview
6.10.3 Kexing Biopharm Short-acting EPO Drugs Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Kexing Biopharm Short-acting EPO Drugs Product Portfolio
6.10.5 Kexing Biopharm Recent Developments/Updates
6.11 Harbin Pharmaceutical Group
6.11.1 Harbin Pharmaceutical Group Company Information
6.11.2 Harbin Pharmaceutical Group Description and Business Overview
6.11.3 Harbin Pharmaceutical Group Short-acting EPO Drugs Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Harbin Pharmaceutical Group Short-acting EPO Drugs Product Portfolio
6.11.5 Harbin Pharmaceutical Group Recent Developments/Updates
6.12 Beijing Four Rings Bio-Pharmaceutical
6.12.1 Beijing Four Rings Bio-Pharmaceutical Company Information
6.12.2 Beijing Four Rings Bio-Pharmaceutical Description and Business Overview
6.12.3 Beijing Four Rings Bio-Pharmaceutical Short-acting EPO Drugs Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Beijing Four Rings Bio-Pharmaceutical Short-acting EPO Drugs Product Portfolio
6.12.5 Beijing Four Rings Bio-Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Short-acting EPO Drugs Industry Chain Analysis
7.2 Short-acting EPO Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Short-acting EPO Drugs Production Mode & Process Analysis
7.4 Short-acting EPO Drugs Sales and Marketing
7.4.1 Short-acting EPO Drugs Sales Channels
7.4.2 Short-acting EPO Drugs Distributors
7.5 Short-acting EPO Drugs Customer Analysis
8 Short-acting EPO Drugs Market Dynamics
8.1 Short-acting EPO Drugs Industry Trends
8.2 Short-acting EPO Drugs Market Drivers
8.3 Short-acting EPO Drugs Market Challenges
8.4 Short-acting EPO Drugs Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Short-acting EPO Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Short-acting EPO Drugs Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Short-acting EPO Drugs Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Short-acting EPO Drugs Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Short-acting EPO Drugs Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Short-acting EPO Drugs Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Short-acting EPO Drugs Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Short-acting EPO Drugs Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Short-acting EPO Drugs, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Short-acting EPO Drugs, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Short-acting EPO Drugs, Product Type & Application
 Table 12. Global Key Manufacturers of Short-acting EPO Drugs, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Short-acting EPO Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Short-acting EPO Drugs as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Short-acting EPO Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Short-acting EPO Drugs Sales by Region (2020-2025) & (K Units)
 Table 18. Global Short-acting EPO Drugs Sales Market Share by Region (2020-2025)
 Table 19. Global Short-acting EPO Drugs Sales by Region (2026-2031) & (K Units)
 Table 20. Global Short-acting EPO Drugs Sales Market Share by Region (2026-2031)
 Table 21. Global Short-acting EPO Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Short-acting EPO Drugs Revenue Market Share by Region (2020-2025)
 Table 23. Global Short-acting EPO Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Short-acting EPO Drugs Revenue Market Share by Region (2026-2031)
 Table 25. North America Short-acting EPO Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Short-acting EPO Drugs Sales by Country (2020-2025) & (K Units)
 Table 27. North America Short-acting EPO Drugs Sales by Country (2026-2031) & (K Units)
 Table 28. North America Short-acting EPO Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Short-acting EPO Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Short-acting EPO Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Short-acting EPO Drugs Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Short-acting EPO Drugs Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Short-acting EPO Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Short-acting EPO Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Short-acting EPO Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Short-acting EPO Drugs Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Short-acting EPO Drugs Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Short-acting EPO Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Short-acting EPO Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Short-acting EPO Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Short-acting EPO Drugs Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Short-acting EPO Drugs Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Short-acting EPO Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Short-acting EPO Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Short-acting EPO Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Short-acting EPO Drugs Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Short-acting EPO Drugs Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Short-acting EPO Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Short-acting EPO Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Short-acting EPO Drugs Sales (K Units) by Type (2020-2025)
 Table 51. Global Short-acting EPO Drugs Sales (K Units) by Type (2026-2031)
 Table 52. Global Short-acting EPO Drugs Sales Market Share by Type (2020-2025)
 Table 53. Global Short-acting EPO Drugs Sales Market Share by Type (2026-2031)
 Table 54. Global Short-acting EPO Drugs Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Short-acting EPO Drugs Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Short-acting EPO Drugs Revenue Market Share by Type (2020-2025)
 Table 57. Global Short-acting EPO Drugs Revenue Market Share by Type (2026-2031)
 Table 58. Global Short-acting EPO Drugs Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Short-acting EPO Drugs Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Short-acting EPO Drugs Sales (K Units) by Application (2020-2025)
 Table 61. Global Short-acting EPO Drugs Sales (K Units) by Application (2026-2031)
 Table 62. Global Short-acting EPO Drugs Sales Market Share by Application (2020-2025)
 Table 63. Global Short-acting EPO Drugs Sales Market Share by Application (2026-2031)
 Table 64. Global Short-acting EPO Drugs Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Short-acting EPO Drugs Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Short-acting EPO Drugs Revenue Market Share by Application (2020-2025)
 Table 67. Global Short-acting EPO Drugs Revenue Market Share by Application (2026-2031)
 Table 68. Global Short-acting EPO Drugs Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Short-acting EPO Drugs Price (US$/Unit) by Application (2026-2031)
 Table 70. Amgen Company Information
 Table 71. Amgen Description and Business Overview
 Table 72. Amgen Short-acting EPO Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Amgen Short-acting EPO Drugs Product
 Table 74. Amgen Recent Developments/Updates
 Table 75. Johnson & Johnson Company Information
 Table 76. Johnson & Johnson Description and Business Overview
 Table 77. Johnson & Johnson Short-acting EPO Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Johnson & Johnson Short-acting EPO Drugs Product
 Table 79. Johnson & Johnson Recent Developments/Updates
 Table 80. Roche Company Information
 Table 81. Roche Description and Business Overview
 Table 82. Roche Short-acting EPO Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Roche Short-acting EPO Drugs Product
 Table 84. Roche Recent Developments/Updates
 Table 85. Kyowa Kirin Company Information
 Table 86. Kyowa Kirin Description and Business Overview
 Table 87. Kyowa Kirin Short-acting EPO Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Kyowa Kirin Short-acting EPO Drugs Product
 Table 89. Kyowa Kirin Recent Developments/Updates
 Table 90. LG Chem Company Information
 Table 91. LG Chem Description and Business Overview
 Table 92. LG Chem Short-acting EPO Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. LG Chem Short-acting EPO Drugs Product
 Table 94. LG Chem Recent Developments/Updates
 Table 95. Daewoong Pharmaceutical Company Information
 Table 96. Daewoong Pharmaceutical Description and Business Overview
 Table 97. Daewoong Pharmaceutical Short-acting EPO Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Daewoong Pharmaceutical Short-acting EPO Drugs Product
 Table 99. Daewoong Pharmaceutical Recent Developments/Updates
 Table 100. Wockhardt Company Information
 Table 101. Wockhardt Description and Business Overview
 Table 102. Wockhardt Short-acting EPO Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Wockhardt Short-acting EPO Drugs Product
 Table 104. Wockhardt Recent Developments/Updates
 Table 105. CJ Healthcare Company Information
 Table 106. CJ Healthcare Description and Business Overview
 Table 107. CJ Healthcare Short-acting EPO Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. CJ Healthcare Short-acting EPO Drugs Product
 Table 109. CJ Healthcare Recent Developments/Updates
 Table 110. 3SBio Company Information
 Table 111. 3SBio Description and Business Overview
 Table 112. 3SBio Short-acting EPO Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. 3SBio Short-acting EPO Drugs Product
 Table 114. 3SBio Recent Developments/Updates
 Table 115. Kexing Biopharm Company Information
 Table 116. Kexing Biopharm Description and Business Overview
 Table 117. Kexing Biopharm Short-acting EPO Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 118. Kexing Biopharm Short-acting EPO Drugs Product
 Table 119. Kexing Biopharm Recent Developments/Updates
 Table 120. Harbin Pharmaceutical Group Company Information
 Table 121. Harbin Pharmaceutical Group Description and Business Overview
 Table 122. Harbin Pharmaceutical Group Short-acting EPO Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 123. Harbin Pharmaceutical Group Short-acting EPO Drugs Product
 Table 124. Harbin Pharmaceutical Group Recent Developments/Updates
 Table 125. Beijing Four Rings Bio-Pharmaceutical Company Information
 Table 126. Beijing Four Rings Bio-Pharmaceutical Description and Business Overview
 Table 127. Beijing Four Rings Bio-Pharmaceutical Short-acting EPO Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 128. Beijing Four Rings Bio-Pharmaceutical Short-acting EPO Drugs Product
 Table 129. Beijing Four Rings Bio-Pharmaceutical Recent Developments/Updates
 Table 130. Key Raw Materials Lists
 Table 131. Raw Materials Key Suppliers Lists
 Table 132. Short-acting EPO Drugs Distributors List
 Table 133. Short-acting EPO Drugs Customers List
 Table 134. Short-acting EPO Drugs Market Trends
 Table 135. Short-acting EPO Drugs Market Drivers
 Table 136. Short-acting EPO Drugs Market Challenges
 Table 137. Short-acting EPO Drugs Market Restraints
 Table 138. Research Programs/Design for This Report
 Table 139. Key Data Information from Secondary Sources
 Table 140. Key Data Information from Primary Sources
 Table 141. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Short-acting EPO Drugs
 Figure 2. Global Short-acting EPO Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Short-acting EPO Drugs Market Share by Type: 2024 & 2031
 Figure 4. Epoetin-alfa Product Picture
 Figure 5. Epoetin-beta Product Picture
 Figure 6. Darbepoetin-alfa Product Picture
 Figure 7. Others Product Picture
 Figure 8. Global Short-acting EPO Drugs Market Value by Application (2020-2031) & (US$ Million)
 Figure 9. Global Short-acting EPO Drugs Market Share by Application: 2024 & 2031
 Figure 10. Anemia
 Figure 11. Kidney Disorders
 Figure 12. Others
 Figure 13. Global Short-acting EPO Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Short-acting EPO Drugs Market Size (2020-2031) & (US$ Million)
 Figure 15. Global Short-acting EPO Drugs Sales (2020-2031) & (K Units)
 Figure 16. Global Short-acting EPO Drugs Average Price (US$/Unit) & (2020-2031)
 Figure 17. Short-acting EPO Drugs Report Years Considered
 Figure 18. Short-acting EPO Drugs Sales Share by Manufacturers in 2024
 Figure 19. Global Short-acting EPO Drugs Revenue Share by Manufacturers in 2024
 Figure 20. Global 5 and 10 Largest Short-acting EPO Drugs Players: Market Share by Revenue in Short-acting EPO Drugs in 2024
 Figure 21. Short-acting EPO Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 22. Global Short-acting EPO Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 23. North America Short-acting EPO Drugs Sales Market Share by Country (2020-2031)
 Figure 24. North America Short-acting EPO Drugs Revenue Market Share by Country (2020-2031)
 Figure 25. United States Short-acting EPO Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Canada Short-acting EPO Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. Europe Short-acting EPO Drugs Sales Market Share by Country (2020-2031)
 Figure 28. Europe Short-acting EPO Drugs Revenue Market Share by Country (2020-2031)
 Figure 29. Germany Short-acting EPO Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. France Short-acting EPO Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. U.K. Short-acting EPO Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Italy Short-acting EPO Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Russia Short-acting EPO Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Asia Pacific Short-acting EPO Drugs Sales Market Share by Region (2020-2031)
 Figure 35. Asia Pacific Short-acting EPO Drugs Revenue Market Share by Region (2020-2031)
 Figure 36. China Short-acting EPO Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Japan Short-acting EPO Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. South Korea Short-acting EPO Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. India Short-acting EPO Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Australia Short-acting EPO Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. China Taiwan Short-acting EPO Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Southeast Asia Short-acting EPO Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Latin America Short-acting EPO Drugs Sales Market Share by Country (2020-2031)
 Figure 44. Latin America Short-acting EPO Drugs Revenue Market Share by Country (2020-2031)
 Figure 45. Mexico Short-acting EPO Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Brazil Short-acting EPO Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Argentina Short-acting EPO Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Colombia Short-acting EPO Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Middle East and Africa Short-acting EPO Drugs Sales Market Share by Country (2020-2031)
 Figure 50. Middle East and Africa Short-acting EPO Drugs Revenue Market Share by Country (2020-2031)
 Figure 51. Turkey Short-acting EPO Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Saudi Arabia Short-acting EPO Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. UAE Short-acting EPO Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. Global Sales Market Share of Short-acting EPO Drugs by Type (2020-2031)
 Figure 55. Global Revenue Market Share of Short-acting EPO Drugs by Type (2020-2031)
 Figure 56. Global Short-acting EPO Drugs Price (US$/Unit) by Type (2020-2031)
 Figure 57. Global Sales Market Share of Short-acting EPO Drugs by Application (2020-2031)
 Figure 58. Global Revenue Market Share of Short-acting EPO Drugs by Application (2020-2031)
 Figure 59. Global Short-acting EPO Drugs Price (US$/Unit) by Application (2020-2031)
 Figure 60. Short-acting EPO Drugs Value Chain
 Figure 61. Channels of Distribution (Direct Vs Distribution)
 Figure 62. Bottom-up and Top-down Approaches for This Report
 Figure 63. Data Triangulation
 Figure 64. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Nano Dimension

SIMILAR REPORTS